West Expands Research and Development Center

West Expands Research and Development Center
Focus is on Helping Customers meet Stringent Quality Requirements

LIONVILLE, Pa.--(BUSINESS WIRE)--West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, is expanding its research and development center in St. Petersburg, Fla. West's advanced development center will focus on new elastomer formulations, process technologies and products for West's global component manufacturing network.

"The customer-focused activities at the advanced development center will enable West to optimize product development and manufacturing processes so we can help customers meet their business objectives, such as quality by design initiatives," said Fran DeGrazio, Vice President, Marketing and Strategic Business Development, West. "Our goal continues to be providing innovative packaging system components and drug administration solutions. One way we do that is to understand and eliminate variation in our products, which helps our customers reduce their exposure to risk. As quality requirements increase, global pharmaceutical manufacturers are seeking early partnerships with packaging manufacturers such as West to help mitigate risk by building quality into the product from research and development through delivery of the drug to the patient."

"This investment enables us to continue to support our customers' requirements for extremely clean pharmaceutical packaging and delivery system components by introducing new innovative technologies and by building on our established technologies, including the Westar® ready-to-use process, FluroTec® barrier film and Envision® automated vision inspection system," said Tyson Popp, Vice President, Research and Development, West.

The advanced development center will feature the newest technologies for mixing, compounding, molding and finishing elastomer packaging components. West expects the advanced development center to be on-line by October 2011.

About West

West's innovative system, device and component solutions help improve the safety and administration of injectable drugs. West's proprietary materials science, formulation research and manufacturing technologies advance the quality, therapeutic value, development speed and rapid market availability of pharmaceuticals, biologics and vaccines. Sales in 2010 totaled US$1.1 billion.

West supports its customers from sales, manufacturing, customer support and research and development from locations in North and South America, Europe, Asia and Australia. Global headquarters are in Lionville, Pa., USA. Visit West online at http://www.westpharma.com and www.westPFSsolutions.com. Follow us on Twitter: www.twitter.com/WestPharma.

Westar®, FluroTec® and Envision® are registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.

FluroTec technology is licensed from Daikyo Seiko, Ltd.

Contacts
Schwartz Communications
Risa Goldman Burgess, 781-684-0770
[email protected]

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.